- UK's Starmer rules out austerity as Labour conference opens
- Swiss voters reject environment, pensions reforms: projected results
- Israel says 'landed blows' on Hezbollah as Lebanon violence intensifies
- Roma CEO steps down amid anger over club icon De Rossi's sacking
- Incoming French government under pressure on multiple fronts
- Hezbollah rockets strike near Israel's Haifa as UN warns of 'catastrophe'
- Haddad Maia roars back to beat Kasatkina in Korea Open final
- All-rounder Ashwin powers India to 280-run Test win over Bangladesh
- Failed Springbok 'gamble' sets up rugby championship decider
- Lebanon strikes send Israelis to shelters as UN warns of 'catastrophe'
- Far-right AfD eyes new win in east German state vote
- Tony Popovic set to become new Socceroos coach - reports
- All-round Ashwin powers India to big Test win over Bangladesh
- NZ chase 275 to win first Sri Lanka Test after Patel bags six
- Ashwin bags six wickets as India hammer Bangladesh in first Test
- Nascent French government under pressure on multiple fronts
- Angry French cognac makers see red over Chinese tariffs threat
- Protect the prosciutto: Italy battles swine fever
- UN holds 'Summit of the Future' to tackle global crises
- Marxist leader set to become Sri Lanka's next president
- From blades to pull-up bars: UK charity tackles knife crime
- Swiss vote on pensions and environment protections
- No pain, no gain: Chinese pro wrestlers fight for recognition
- UAE leader seeks to deepen 'strategic' ties in US visit during Mideast crisis
- Hezbollah takes heavy hits but still fighting Israel
- Floods, landslides hit central Japan months after major quake
- All Blacks coach Robertson demands better finishing
- Argentina edge South Africa to keep title hopes alive
- Biden says China 'testing us,' in hot mic remarks to Quad allies
- Dubois destroys Joshua to retain IBF world heavyweight crown
- Guardiola says critics want Man City wiped 'from face of the Earth'
- Biden says 'Quad' is 'here to stay' despite challenges
- Dubois knocks out Joshua to retain IBF world heavyweight crown
- Vinicius helps 'faster' Madrid overturn stubborn Espanyol
- Zelensky to press US on long-range missile strikes inside Russia
- PSG drop first points in draw at Reims
- Vinicius, Mbappe on target as Madrid crush plucky Espanyol
- Jeeno leads Ko by two at LPGA Queen City Championship
- Bottega Veneta goes for 'E.T.' chic as Madonna pops into D&G
- Messi, Miami frustrated by New York late leveler
- Musk's X platform takes first step toward lifting Brazil ban
- 'Business as usual' for Australia match-winner Carey amid boos
- Israeli jets pound Lebanon after deadly Beirut strike
- Ten Hag bemoans Man Utd's lack of killer instinct in Palace stalemate
- France's Macron appoints new government in shift to right
- Cheika proud of Leicester grit after winning start as boss
- Profligate Man Utd pay price in 0-0 draw at Palace
- Kane, Olise run riot as Bayern thump Bremen
- Diaz fires Liverpool top of Premier League, Man Utd held at Palace
- LIV champion Rahm out of LIV Team semis with severe flu
Drugmakers agree to US govt price talks amid pushback
Major drugmakers have grudgingly agreed to negotiate on reducing prices for 10 medicines, the White House said Tuesday, a key element in President Joe Biden's push to lower healthcare costs ahead of the 2024 election.
Under the initiative, the federal government is using new powers to negotiate the prices of drugs covered by Medicare, the massive health insurance program for people 65 and older.
Biden's landmark Inflation Reduction Act (IRA), the major legislative package of energy transition policy and social reforms he signed last year, allowed Medicare to begin negotiating drug prices for the first time in its nearly 60-year existence.
The White House said makers of 10 medicines for serious illnesses, selected earlier in the year for price negotiations with the US government, have all agreed to participate in the talks ahead of an October 1 deadline.
The drugs include Farxiga by AstraZeneca used against diabetes, and Entresto by Novartis used to treat heart failure.
The treatments also include the anticoagulant Eliquis, used by more than 3.7 million Medicare beneficiaries.
The government is limited at first to choosing only 10 drugs for price negotiations, but can expand the program in subsequent years.
- 'Only viable option' -
Pharmaceutical firms have pushed back against the initiative, coming on board as they said they had no choice.
There are steep consequences for not participating in talks -- manufacturers that fail to comply with the program could face tax penalties.
Novartis said in a statement that it signed the negotiation program agreement as "this was our only viable option."
"If we had not signed the agreement, Novartis would face excessive and crippling fines," a spokesman added.
The company argues that the price-setting provisions are "unconstitutional."
Some firms like Amgen said they signed the manufacturer agreement for the program "in light of the statutory deadline."
But Amgen added it believes the scheme "is unlawful and will impede medical progress" on key therapies.
A Johnson & Johnson spokesperson told AFP: "We continue to believe the IRA's drug price-setting provisions are damaging to the innovation ecosystem."
- Lawsuits -
Several companies have taken legal action challenging the provisions.
Novo Nordisk said these "subject the company's medicines to unconstitutional government-imposed price controls" in announcing its lawsuit last Friday.
Merck in June filed a suit calling the program an unconstitutional "extortion" that would harm pharmaceutical innovation.
"In total, the 10 drugs selected for negotiation accounted for $3.4 billion in out-of-pocket costs for an estimated nine million Medicare enrollees in 2022," the White House said Tuesday.
It called the latest development a "major step towards lower health care costs for seniors and families."
The United States pays on average 2.5 times more for prescription drugs than other developed countries such as France, according to a Rand Corporation study.
Biden, who is campaigning for reelection with a heavy focus on easing voters' financial woes, hailed the price negotiation developments last year as potentially life-altering for millions of Americans.
The change in prices for the 10 drugs are not set to come into effect until January 2026.
Medicare is set to negotiate prices for up to 60 drugs in the next four years, and up to an additional 20 drugs each year after that.
L.Davis--AMWN